PTGS2 and Parkinson disease: In support of this finding, our results showed a notable increase of iNOS and COX-2 both in vivo and in vitro model of PD, while treatment with TO901317 significantly reduced their expression; this is strictly correlated to the production of ROS, a consequence of microglia activation in parkinsonian patients [30].